top of page
The Professional Network for Healthcare Experts
Merck licenses SciBrunch KRAS G12D inhibitor in deal worth up to $2.13bn
Merck has secured exclusive worldwide rights to SciBrunch Therapeutics' preclinical KRAS G12D inhibitor SPR2015 in an oncology licensing transaction worth up to $2.13 billion.
nuaxia
3 days ago2 min read
FDA approves Welireg plus Lenvima for advanced clear-cell renal cell carcinoma after immunotherapy
The FDA has approved Welireg in combination with Lenvima for adults with advanced clear-cell renal cell carcinoma following prior PD-1 or PD-L1 immunotherapy.
nuaxia
7 days ago2 min read
Kelun’s Merck-Partnered ADC Delivers Phase III Win in First-Line PD-L1-Negative Lung Cancer
Sacituzumab tirumotecan plus Keytruda improves progression-free survival in advanced NSCLC, expanding potential role of ADC-immunotherapy combinations.
nuaxia
Jul 173 min read
Merck’s Lipfendra Becomes First FDA-Approved Oral PCSK9 Inhibitor for High Cholesterol
Oral cholesterol therapy offers an alternative to injectable PCSK9 inhibitors as Merck targets multi-billion-dollar cardiovascular market.
nuaxia
Jul 173 min read
Merck KGaA Expands Life Sciences Business with $11.3bn Bio-Techne Acquisition
Merck KGaA has agreed to acquire US-based life sciences company Bio-Techne, significantly expanding its presence across the life sciences value chain.
nuaxia
Jun 303 min read
Merck Expands AI Drug Discovery Push with $510m Protillion Partnership
Merck & Co. has strengthened its commitment to AI-driven drug discovery through a new multi-year partnership with Protillion Biosciences, signing a deal worth up to $510 million focused on identifying and engineering novel therapeutic candidates.
nuaxia
Jun 213 min read
FDA backs Merck’s dual-pronged push in kidney cancer with Welireg–Keytruda combo approval
The US Food and Drug Administration (FDA) has approved a combination regimen of Merck & Co.’s Keytruda (pembrolizumab) and Welireg (belzutifan).
nuaxia
Jun 152 min read
Merck’s $6.7B Terns Deal Shows Big Pharma Is Preparing for Patent Cliffs
Merck has agreed to acquire biotechnology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion, strengthening its oncology pipeline ahead of the upcoming patent expiry of its blockbuster drug, Keytruda.
nuaxia
Mar 302 min read
bottom of page